Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BY 4.0Oncology Research

Single-Cell and Spatial Insights into Oral Squamous Cell Carcinoma: Towards Cell-State-Targeted Immunotherapy

  1. 1Department of Stomatology, Stomatological Hospital of Southern Medical University, Guangzhou, China
  2. 2Department of Stomatology, Xianyang Central Hospital, Xianyang, China

Abstract

Oral squamous cell carcinoma (OSCC) remains associated with substantial morbidity and mortality, and only a subset of patients derive durable benefit from immune-checkpoint blockade. Single-cell and spatial approaches reveal cellular states and tissue organization that bulk profiling cannot resolve. These findings suggest that therapeutic responses may depend on both cellular function and the local interactions that sustain it. This narrative review integrates single-cell transcriptomic, spatial, functional and clinical studies of the OSCC microenvironment. We distinguish OSCC-specific findings from broader head and neck squamous cell carcinoma and pan-cancer evidence. Computational inference, tissue association, experimental perturbation and clinical validation are considered separately. Malignant, myeloid, fibroblast, vascular and lymphoid states form spatially organized niches whose composition varies across anatomical sites and treatment settings. We examine their relevance to immune escape and chemotherapy resistance and assess strategies directed at specific cell states and intercellular circuits. Although selected circuits have functional support in experimental models, many spatial signatures remain observational and lack clinical validation. Clinical translation will require reproducible tissue assays, causal testing of candidate interactions and independent biomarker validation. Practical considerations include marker-panel selection, spatial scoring, tissue availability and the feasibility of sampling primary tumors and metastatic sites before, during and after treatment. Prospective studies must also determine whether biomarker-guided treatment improves outcomes, rather than assuming that a spatial association predicts therapeutic benefit. This review aims to critically synthesize current evidence, identify key knowledge gaps and define requirements for translating cell-state and spatial-niche insights into selective immunotherapeutic strategies for OSCC.

Related

  1. Anti-PD-L1 antibody-coated metal-organic framework for targeted PTPN2 Inhibitor delivery and enhanced immunotherapy of head and neck squamous cell carcinoma
    Zhanpeng Zhu, Rui Wang, Wei Li +1
    International Journal of Pharmaceutics: XPeer-reviewedCC BY-NCFull textOncologyDOAJEurope PMCPMC
  2. Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy
    Jiangmin Zhou, Huifang Xiong, Honghao Zhou +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Spatial Remodeling of the Immune Microenvironment During Laryngeal Carcinogenesis Reveals Prognostic Immune Patterns in Laryngeal Squamous Cell Carcinoma
    Toni Vidović, Filip Tudor, Blažen Marijić +3
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  4. 1190 Spatial and phenotypic characterization of tertiary lymphoid structures and immune organization in cutaneous squamous cell carcinoma using multiplex immunofluorescence
    Diwakar Davar, Markus Schober, S Chakra Chennubhotla +8
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. Drug-eluting bead transarterial chemoembolization with immunotherapy and targeted therapy for advanced clear cell renal cell carcinoma: A case report.
    Yin Gao, Qiang Xu, Dongxu Kang +1
    Oncology lettersPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
BibTeX
@article{chen2026singlecell,
  title = {{Single-Cell and Spatial Insights into Oral Squamous Cell Carcinoma: Towards Cell-State-Targeted Immunotherapy}},
  author = {Yang Chen and Lirong Hou},
  journal = {Oncology Research},
  year = {2026},
  month = oct,
  doi = {10.32604/or.2026.091624},
  url = {https://doi.org/10.32604/or.2026.091624},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Single-Cell and Spatial Insights into Oral Squamous Cell Carcinoma: Towards Cell-State-Targeted Immunotherapy
AU  - Yang Chen
AU  - Lirong Hou
PY  - 2026
DA  - 2026/10/28
JO  - Oncology Research
DO  - 10.32604/or.2026.091624
UR  - https://doi.org/10.32604/or.2026.091624
AB  - Oral squamous cell carcinoma (OSCC) remains associated with substantial morbidity and mortality, and only a subset of patients derive durable benefit from immune-checkpoint blockade. Single-cell and spatial approaches reveal cellular states and tissue organization that bulk profiling cannot resolve. These findings suggest that therapeutic responses may depend on both cellular function and the local interactions that sustain it. This narrative review integrates single-cell transcriptomic, spatial, functional and clinical studies of the OSCC microenvironment. We distinguish OSCC-specific findings from broader head and neck squamous cell carcinoma and pan-cancer evidence. Computational inference, tissue association, experimental perturbation and clinical validation are considered separately. Malignant, myeloid, fibroblast, vascular and lymphoid states form spatially organized niches whose composition varies across anatomical sites and treatment settings. We examine their relevance to immune escape and chemotherapy resistance and assess strategies directed at specific cell states and intercellular circuits. Although selected circuits have functional support in experimental models, many spatial signatures remain observational and lack clinical validation. Clinical translation will require reproducible tissue assays, causal testing of candidate interactions and independent biomarker validation. Practical considerations include marker-panel selection, spatial scoring, tissue availability and the feasibility of sampling primary tumors and metastatic sites before, during and after treatment. Prospective studies must also determine whether biomarker-guided treatment improves outcomes, rather than assuming that a spatial association predicts therapeutic benefit. This review aims to critically synthesize current evidence, identify key knowledge gaps and define requirements for translating cell-state and spatial-niche insights into selective immunotherapeutic strategies for OSCC.
SN  - 0965-0407
SN  - 1555-3906
ER  -